The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of inclusion body myositis,” published in the March 2025 issue of Rheumatology by ...

New research examining the skeletal muscle cells of patients with inclusion body myositis (IBM) has revealed that the nucleic acid-binding protein TDP-43, which is normally restricted to the ...

Inclusion body myositis (IBM) is an inflammatory myopathy causing proximal and distal muscle weakness. IBM’s cause remains unknown, lacking validated models, biomarkers and effective treatment ...

US-based biotech Abcuro has raised $200m to advance the development of its monoclonal antibody ulviprubart in the rare muscle disease called inclusion body myositis (IBM). The funding round ...

This report offers in-depth insights into the Inclusion Body Myositis (IBM) pipeline, showcasing the continuing efforts of over 2 companies and the development of more than 3 pipeline drugs ...

Now, the veteran guitarist and singer-songwriter is making medical history as he bravely battles inclusion body myositis. IBM ...

US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of lead drug ulviprubart and file it for approval for inclusion body ...

Ulviprubart is designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia ...

This report offers in-depth insights into the Inclusion Body Myositis (IBM) pipeline, showcasing the continuing efforts of over 2 companies and the development of more than 3 pipeline drugs projected ...